Codon optimized RPGRORF15 genes and uses thereof
The present disclosure provides codon optimized RPGRorf15 sequences, vectors, and host cells comprising codon optimized RPGRorf15 sequences, and methods of treating retinal disorders such as XLRP comprising administering to the subject a codon optimized RPGRorf15 sequence.
1. A nucleic acid encoding human retinitis pigmentosa GTPase regulator (RPGR) protein of SEQ ID NO:2 and codon optimized for expression in humans, the nucleic acid comprising the nucleotide sequence set forth as SEQ ID NO: 1 or comprising a nucleotide sequence at least 95% identical thereto, wherein the nucleic acid is expressed in a host cell at a greater level compared with the level of expression of the wild type RPGR nucleotide sequence of SEQ ID NO: 3 in the host cell under the same conditions.
2. The nucleic acid according to claim 1 , wherein the nucleotide sequence has a codon adaptation index of at least 0.89.
3. The nucleic acid according to claim 1 , comprising the nucleotide sequence set forth as SEQ ID NO: 1.
4. An expression cassette comprising a nucleic acid according to claim 1 , wherein the nucleotide sequence set forth as SEQ ID NO: 1 or the nucleotide sequence at least 95% identical thereto is operably linked to an expression control sequence.
5. The expression cassette of claim 4 , wherein the expression control sequence is a constitutive promoter or is a promoter that directs preferential expression of the nucleic acid in rod and cone cells.
6. The expression cassette of claim 5 , wherein the expression control sequence is a human G protein-coupled receptor rhodopsin kinase 1 (hGRK) promoter.
7. The expression cassette of claim 6 , comprising from 5′ to 3′: (a) an AAV2 terminal repeat (b) an hGRK promoter (c) codon optimized RPGRorf15 gene of SEQ ID NO:1 (d) an SV40 polyadenylation sequence and (e) an AAV2 terminal repeat.
8. The expression cassette of claim 7 , wherein the 5′ AAV2 terminal repeat has the nucleotide sequence set forth as SEQ ID NO:6 and/or wherein the hGRK promoter has the nucleotide sequence set forth as SEQ ID NO:4 and/or wherein the SV40 polyadenylation sequence has the nucleotide sequence set forth as SEQ ID NO:8 and/or wherein the 3′ AAV2 terminal repeat has the nucleotide sequence set forth as SEQ ID NO:7.
9. The expression cassette of claim 8 , comprising or consisting of the nucleotide sequence of SEQ ID NO:5 or a sequence at least at least 95% identical thereto.
10. A recombinant adeno-associated virus (rAAV) vector comprising a heterologous nucleic acid comprising the expression cassette according to claim 4 .
11. The rAAV vector of claim 10 , wherein the rAAV vector comprises an AAV capsid of serotype 2, 5 or 8 or a variant thereof.
12. The rAAV vector of claim 11 , wherein the rAAV vector comprises a variant AAV capsid protein comprising the amino acid sequence of SEQ ID NO:9.
13. The rAAV vector of claim 12 , wherein the rAAV vector comprises a nucleic acid comprising from 5′ to 3′: (a) an AAV2 terminal repeat (b) an hGRK promoter (c) codon optimized RPGRorf15 gene of SEQ ID NO:1 and (d) an AAV2 terminal repeat.
14. The rAAV vector of claim 13 , wherein the 5′ AAV2 terminal repeat has the nucleotide sequence set forth as SEQ ID NO:6 and/or wherein the hGRK promoter has the nucleotide sequence set forth as SEQ ID NO:4 and/or wherein the SV40 polyadenylation sequence has the nucleotide sequence set forth as SEQ ID NO:8 and/or wherein the 3′ AAV2 terminal repeat has the nucleotide sequence set forth as SEQ ID NO:7.
15. The rAAV vector of claim 14 , wherein the rAAV vector comprises a nucleic acid comprising the nucleotide sequence of SEQ ID NO:5 or a sequence at least 95% identical thereto.
16. The rAAV vector of claim 15 , wherein the rAAV vector comprises (i) a capsid comprising a capsid protein comprising or consisting of the sequence of SEQ ID NO:9 and (ii) a nucleic acid comprising or consisting of the nucleotide sequence of SEQ ID NO:5.
17. A method for treating XLRP in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of pharmaceutical composition comprising an rAAV vector according to claim 13 and a pharmaceutically acceptable excipient, whereby the XLRP is treated in the human subject.
18. The method according to claim 17 , wherein the 5′ AAV2 terminal repeat has the nucleotide sequence set forth as SEQ ID NO:6 and/or wherein the hGRK promoter has the nucleotide sequence set forth as SEQ ID NO:4 and/or wherein the SV40 polyadenylation sequence has the nucleotide sequence set forth as SEQ ID NO:8 and/or wherein the 3′ AAV2 terminal repeat has the nucleotide sequence set forth as SEQ ID NO:7.
19. The method according to claim 18 , wherein the rAAV vector comprises (i) a capsid comprising a capsid protein comprising or consisting of the sequence of SEQ ID NO:9 and (ii) a nucleic acid comprising or consisting of the nucleotide sequence of SEQ ID NO:5.
20. The method according to claim 19 , wherein the pharmaceutical composition is administered to the subject by periocular, intravitreal, suprachoroidal or subretinal injection.
21. The method according to claim 20 , wherein the vector is administered to the subject at a dosage from 10 10 vector genomes (vg)/eye to 10 13 vg/eye.
22. The method according to claim 21 , wherein the vector is administered to the subject at a dosage from 1×10 11 vg/eye to 5×10 12 vg/eye.
23. The method according to according to claim 22 , wherein the vector is administered to the subject at a dosage of 3×10 11 vg/eye or at a dosage of 1×10 12 vg/eye.
24. A pharmaceutical composition comprising an rAAV according to claim 16 and at least one pharmaceutically acceptable excipient.
25. The pharmaceutical composition according to claim 24 , wherein the pharmaceutical composition comprises between 10 9 vg and 10 14 vg of the rAAV or comprises between 10 10 vg and 10 13 vg of the rAAV, or comprises 3×10 11 vg or 1×10 12 vg of the rAAV.